May 18, 2020 / 11:20 AM / 8 days ago

BRIEF-Can-Fite Reports Additional Findings From Successful Phase II Nash Study

May 18 (Reuters) - Can Fite Biopharma Ltd:

* CAN-FITE REPORTS ADDITIONAL FINDINGS FROM SUCCESSFUL PHASE II NASH STUDY: 25 MG DOSE OF NAMODENOSON SIGNIFICANTLY REDUCED LIVER FAT AND FIBROSIS

* CAN FITE BIOPHARMA LTD - ALL CASES OF NASH SIGNIFICANTLY RESOLVED AFTER 12 WEEKS OF TREATMENT WITH NAMODENOSON 25 MG

* CAN FITE BIOPHARMA LTD - NAMODENOSON’S SAFETY PROFILE AND EFFICACY IN PHASE II POSITION DRUG FOR ADVANCED CLINICAL TRIALS IN TREATMENT OF NAFLD/NASH Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below